Controversy remains regarding neoadjuvant approaches in the treatment of pancreatic
cancer. Neoadjuvant therapy has several potential advantages over adjuvant therapy …

Background: The role for neoadjuvant systemic therapy in resectable pancreas
adenocarcinoma remains undefined. Objective: We evaluated the efficacy of gemcitabine …

Purpose To test the safety of neoadjuvant chemotherapy for resectable pancreatic cancer.
Patients and Methods Patients with cytologically proven resectable adenocarcinoma of the …

Objective: To evaluate the morbidity of pancreaticoduodenectomy after neoadjuvant
chemotherapy for resectable pancreatic cancer and to assess its histologic and metabolic …

Background Median OS after surgery in curative intent for non-metastasized pancreas
cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence …

Pancreatic cancer (PC) is the fourth cause of cancer death in Western countries, the only
chance for long term survival is an R0 surgical resection that is feasible in about 10%-20 …

Background Pancreatic cancer carries a dismal prognosis, with surgical resection and
adjuvant therapy offering the only hope for long-term survival. Recently, neoadjuvant …

Objectives: The results of surgical therapy alone for pancreatic cancer are disappointing. We
explored surgical results after neoadjuvant chemoradiation therapy (NACRT) for patients …

Objectives: To retrospectively evaluate the efficacy and tolerability of 5-fluorouracil and low-
dose cisplatin (FP)-based preoperative concurrent chemoradiotherapy (PCRT) and …

AIM: To explore whether preoperative chemoradiation therapy improves survival of patients
with pancreatic cancer undergoing resectional surgery. METHODS: Forty-seven patients …